Actively Recruiting
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
Led by Centre Antoine Lacassagne · Updated on 2024-09-25
106
Participants Needed
1
Research Sites
420 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Thanks to the intrinsic qualities of the proton beam, proton therapy will reduce adverse effects of irradiation. The Proteus®One is the latest generation of proton therapy equipment, enabling the Centre Antoine Lacassagne to expand its range of treatments by carrying out new proton therapy treatments. It has an innovative compact isocentric rotating head (Gantry) that allows the radiation beam to be directed at different angles around the patient. In some cases, two beams are used to treat tumours, and by convention, both beams are delivered during the same session. However, it is necessary to position the patient before each beam, which is time-consuming because 2 beams have to be positioned very precisely each day. The aim of this study is therefore to assess the toxicity of proton therapy delivered by a single daily beam compared with proton therapy delivered by two daily beams, which is the conventional technique.
CONDITIONS
Official Title
Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of chordoma, chondrosarcoma of the skull base or spine, Ewing sarcoma, or osteosarcoma eligible for proton therapy
- Tumor requires treatment with two beams
- MRI scan performed less than one month before treatment
- Performance status between 0 and 2
- Patient has read and signed the informed consent form
- Patient has healthcare insurance coverage
- Age over 18 years
- For women of childbearing age: negative urine pregnancy test and effective contraception during treatment and for six months after treatment
You will not qualify if you...
- Persons deprived of liberty or under guardianship
- Unable to attend medical follow-up due to geographical, social, or psychological reasons
- Patient eligible for symptom reduction surgery
- Vulnerable populations as defined by relevant EU regulations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Antoine lacassagne
Nice, France, 06000
Actively Recruiting
Research Team
C
Clement DEVIC, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here